Bioasis Technologies (FRA:107) Net Change in Cash : €-1.63 Mil (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Bioasis Technologies's Net Change in Cash for the three months ended in Nov. 2022 was €-0.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Nov. 2022 was €-1.63 Mil.

Bioasis Technologies Net Change in Cash Historical Data

The historical data trend for Bioasis Technologies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Net Change in Cash Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Net Change in Cash

Get a 7-Day Free Trial

0.08

0.46

-0.54

1.41

-0.70

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Net Change in Cash	Get a 7-Day Free Trial															-0.65	-0.47	-0.71	-0.15	-0.30

Bioasis Technologies Net Change in Cash Calculation

Bioasis Technologies's Net Change in Cash for the fiscal year that ended in Feb. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-2.52	+	0	+	1.827	+	-0.004
	=	-0.70

Bioasis Technologies's Net Change in Cash for the quarter that ended in Nov. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.323 + 0 + 0 + 0.023

= -0.30

Net Change in Cash for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Bioasis Technologies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Net Change in Cash

Comparable Companies

XCNQ:HAVN XCNQ:WESA.X TSXV:APC.H XCNQ:ENBI XCNQ:MOOD XCNQ:GTTX XCNQ:NSHS XCNQ:MYND XCNQ:ABRT TSXV:PSYB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies Headlines

No Headlines